In pancreatic ductal adenocarcinoma, increased levels of the myCAF (LRRC15+) signature correlated with poor response to anti-PD-L1 therapy in an immunotherapy clinical trial (19). Here, LRRC15 is linked to pancreatic ductal adenocarcinoma.